Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Gains from Sales and Divestitures (2021 - 2025)

PAVmed has reported Gains from Sales and Divestitures over the past 5 years, most recently at $8752.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 93.03% year-over-year to $8752.0; the TTM value through Dec 2025 reached $8752.0, up 93.03%, while the annual FY2025 figure was $8752.0, 93.03% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $8752.0 at PAVmed, down from $261548.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $541666.0 in Q2 2022 and troughed at $1016.0 in Q1 2025.
  • A 5-year average of $145399.2 and a median of $43055.5 in 2022 define the central range for Gains from Sales and Divestitures.
  • Biggest five-year swings in Gains from Sales and Divestitures: surged 219.91% in 2022 and later tumbled 98.15% in 2024.
  • Year by year, Gains from Sales and Divestitures stood at $150000.0 in 2021, then crashed by 75.93% to $36111.0 in 2022, then plummeted by 81.54% to $6666.0 in 2023, then plummeted by 31.98% to $4534.0 in 2024, then soared by 93.03% to $8752.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for PAVM at $8752.0 in Q4 2025, $261548.0 in Q3 2025, and $2032.0 in Q2 2025.